Some industry lobbyists also noted that it was unusual to implement controversial policy changes solely through executive authority just before leaving office. 1
...
The other, the "rebate" rule, would end a widespread practice in which drugmakers give rebates to insurance middlemen in government programs such as Medicare to include those drugs in their plans. 1
